Migrén: nyitott vizsgálatok itt: Puerto Rico

5 nyitott vizsgálatnak van helyszíne itt: Puerto Rico. Regiszteradat; hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

NCT06810505
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Kísérleti kezelés · 3. fázis · AbbVie
Caribbean Medical Research Center Headlands /ID# 271300, San Juan
Regiszter frissítve: 2026-10-09
NCT05711394
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Kísérleti kezelés · 3. fázis · AbbVie
Clinical Research Investigator Group /ID# 261254, Bayamón · Dr. Samuel Sanchez PSC /ID# 248495, Caguas · Puerto Rico Health Institute /ID# 249741, Dorado · PRCCI Clinical Research Center /ID# 262726, San Juan · Caribbean Medical Research Center Headlands /ID# 251634, San Juan
Regiszter frissítve: 2026-10-06
NCT05125302
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Kísérleti kezelés · 3. fázis · AbbVie
Clinical Research Investigator Group /ID# 267454, Bayamón · Puerto Rico Health Institute /ID# 249162, Dorado · GCM Medical Group /ID# 249643, San Juan · Caribbean Medical Research Center Headlands /ID# 265301, San Juan
Regiszter frissítve: 2026-09-14
NCT05707949
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
Kísérleti kezelés · 3. fázis · AbbVie
Clinical Research Investigator Group, LLC /ID# 261251, Bayamón · Dr. Samuel Sanchez PSC /ID# 261670, Caguas · Puerto Rico Health Institute /ID# 250949, Dorado · PRCCI Clinical Research Center /ID# 264232, San Juan · Caribbean Medical Research Center /ID# 253156, San Juan
Regiszter frissítve: 2025-08-11
NCT05127954
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
Kísérleti kezelés · 3. fázis · AbbVie
Clinical Research Investigator Group, LLC /ID# 267458, Bayamón · Puerto Rico Health Institute /ID# 250560, Dorado · GCM Medical Group PSC /ID# 250561, San Juan · Caribbean Medical Research Center /ID# 265292, San Juan
Regiszter frissítve: 2025-07-20

Minden vizsgálat (Migrén) és a térkép

Ez az oldal nem orvosi tanács. Mielőtt egy vizsgálatot megkeresel, beszélj az orvosoddal.

Hibát jelzek

Migrén: nyitott vizsgálatok itt: Puerto Rico

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)